87494-13-1

Basic information

• Product Name: Boc-S-trityl-D-cysteine
• Synonyms: N-alpha-t-Butyloxycarbonyl-S-trityl-D-cysteine;(S)-2-(Tert-butoxycarbonylamino)-3-(tritylthio)propanoic acid;Boc-S-trityl-D-cysteine;Boc-Cys(trt)-OH;Boc-D-Cys(Trt)-OH Boc-S-trityl-D-cysteine;N-Boc-S-trityl-D-cysteine, 98%;Boc-S-trityl-D-cysteine≥ 99% (HPLC);(Tert-Butoxy)Carbonyl D-Cys(Trt)-OH
• CAS NO: 87494-13-1
• Molecular Formula: C₂₇H₂₉NO₄S
• Molecular Weight: 463.59
• Product Categories: Amino Acids
• Mol File: 87494-13-1.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 610.922 °C at 760 mmHg
• Flash Point: 323.274 °C
• Appearance: /
• Density: 1.201 g/cm³
• Refractive Index: 1.599
• Storage Temp.: Store at 0°C
• Solubility: Chloroform (Slightly), DMSO (Slightly), Ethanol (Sparingly)
• PKA: 3.82±0.10(Predicted)
• CAS DataBase Reference: Boc-S-trityl-D-cysteine(CAS DataBase Reference)
• NIST Chemistry Reference: Boc-S-trityl-D-cysteine(87494-13-1)
• EPA Substance Registry System: Boc-S-trityl-D-cysteine(87494-13-1)

Safety Data

• Hazardous Substances Data: 87494-13-1(Hazardous Substances Data)

Usage

Uses

Boc-Cys(Trt)-OH is used in method for preparing ularitide.

InChI:InChI=1/C27H29NO4S/c1-26(2,3)32-25(31)28(23(19-33)24(29)30)27(20-13-7-4-8-14-20,21-15-9-5-10-16-21)22-17-11-6-12-18-22/h4-18,23,33H,19H2,1-3H3,(H,29,30)/t23-/m1/s1

Upstream product

• 1070-19-5 N-(tert-butyloxycarbonyl) azide 
• 2799-07-7 S-trityl-L-cysteine 
• 76-84-6 triphenylmethyl alcohol 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 52-89-1 l-cysteine hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 103213-32-7 N-(9-fluorenylmethoxycarbonyl)-S-trityl-L-cysteine 
• 109-89-7 diethylamine 
• 52-90-4 L-Cysteine 
• 76-83-5 trityl chloride 

Downstream Products

• 33642-47-6 Boc-Cys(Trt)-ONp 
• 67952-00-5 C₁₆H₂₁NO₆S₂ 
• 52071-20-2 N-Boc-S-trityl-L-cys-L-ala-OMe 
• 67952-04-9 Boc-Cys(Trt)-Gly-OCH₂Ph 
• 40472-52-4 Boc-Cys(Trt)-OCP 
• 139924-66-6 (R)-2-tert-Butoxycarbonylamino-3-tritylsulfanyl-propionic acid 2-hydroxy-ethyl ester 
• 70903-37-6 (2S,3S)-2-[(S)-2-((R)-2-tert-Butoxycarbonylamino-3-tritylsulfanyl-propionylamino)-3-(4-hydroxy-phenyl)-propionylamino]-3-methyl-pentanoic acid methyl ester 
• 52071-18-8 N-(tert-butyloxycarbonyl)-S-(triphenylmethyl)-L-cysteinylglycine methyl ester 
• 160876-88-0 [2-((R)-2-tert-Butoxycarbonylamino-3-tritylsulfanyl-propionylamino)-acetylamino]-acetic acid benzyl ester 
• 92278-71-2 Boc-Cys(Trt)-D-Val-O-Bzl 
• 40472-53-5 BOCCys(Trit)ProOH 
• 139924-65-5 ethyleneglycol bis ester of N-Boc S-Trt cysteine 

Relevant articles and documents

Polycysteine as a new type of radio-protector ameliorated tissue injury through inhibiting ferroptosis in mice

Amifostine has been the only small molecule radio-protector approved by FDA for decades; however, the serious adverse effects limit its clinical use. To address the toxicity issues and maintain the good potency, a series of modified small polycysteine peptides had been prepared. Among them, compound 5 exhibited the highest radio-protective efficacy, the same as amifostine, but much better safety profile. To confirm the correlation between the radiation-protective efficacy and the DNA binding capability, each of the enantiomers of the polycysteine peptides had been prepared. As a result, the l-configuration compounds had obviously higher efficacy than the corresponding d-configuration enantiomers; among them, compound 5 showed the highest DNA binding capability and radiation-protective efficacy. To our knowledge, this is the first study that has proved their correlations using direct comparison. Further exploration of the mechanism revealed that the ionizing radiation (IR) triggered ferroptosis inhibition by compound 5 could be one of the pathways for the protection effect, which was different from amifostine. In summary, the preliminary result showed that compound 5, a polycysteine as a new type of radio-protector, had been developed with good efficacy and safety profile. Further study of the compound for potential use is ongoing.

Initial Analysis of the Arylomycin D Antibiotics

The arylomycins are a class of natural product antibiotics that inhibit bacterial type I signal peptidase and are under development as therapeutics. Four classes of arylomycins are known, arylomycins A-D. Previously, we reported the synthesis and analysis of representatives of the A, B, and C classes and showed that their spectrum of activity has the potential to be much broader than originally assumed. Along with a comparison of the mechanism of acquired and innate resistance, this led us to suggest that the arylomycins are latent antibiotics, antibiotics that once possessed broad-spectrum activity, but which upon examination today, have only narrow spectrum activity due to prior selection for resistance in the course of the competition with other microorganisms that drove their evolution in the first place. Interestingly, actinocarbasin, the only identified member of the arylomycin D class, has been reported to have activity against MRSA. To confirm and understand this activity, several actinocarbasin derivatives were synthesized. We demonstrate that the previously reported structure of actinocarbasin is incorrect, identify what is likely the correct scaffold, confirm that scaffold has activity against MRSA, and determine the origin of this activity.

Aminothiol compound, preparation method of aminothiol compound and application of aminothiol compound in radiation protection

The invention discloses an aminothiol compound, a preparation method of the aminothiol compound and application of the aminothiol compound in radiation protection. The compound has a structure shown in the formula I in the description, wherein A1 is selected from -C(O)NR8-, -S(O)2-NR8-, -S(O)NR8- and -R7-NR8-, A2 is selected from carbonyl, sulfonyl, sulfinyl and substituted or unsubstituted C1-6 alkyl, R1, R2, R5 and R6 can be the same or not and are selected from hydrogen and substituted or unsubstituted C1-C5 alkyl or hetero alkyl, n is an integer from 0 to 20000, R3 and R4 are independently selected from hydrogen, X and substituted or unsubstituted C1-6 alkyl, X is selected from F, Cl, Br and I, R7 is selected from substituted or unsubstituted C1-C6 alkyl, and R8 is selected from hydrogen and substituted or unsubstituted C1-C6 alkyl. The compound has the effect of reducing biological injury caused by ionizing radiation and also has the effects of prolonging the lifetime of radiated animals and increasing the survival rate of the radiated animals.